Information
for you...
Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
University of Missouri
CRC-N508 Health Science #1, Hospital Dr, Columbia, MO 65212
Truman Medical Center
2411 Holmes St, SOM M4-329, Kansas City, MO 64108
KU Diabetes Institute - University of Kansas Medical Center
3901 Rainbow Blvd. MS 1064, Kansas City, KS 33160
University of Nebraska Medical Center
985456 Nebraska Medical Center, Omaha, NE 68198
402.559.1193
Cotton-O'Neil Clinical Research Center
3520 SW 6th Avenue, Topeka, KS 66606
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
Teplizumab (Closed to Enrollment-Study Ongoing)
We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Long-Term Investigative Follow-Up in TrialNet (LIFT)
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.